Effect of P2Y12 platelet reactivity level on peri-and postoperative outcomes of cardiac surgery patients

被引:0
|
作者
Chilbert, Maya R. [1 ,2 ,4 ]
Salah, Sara [1 ]
Kersten, Brian [1 ,2 ]
Nitsche, Lindsay [3 ]
Castoro, Nicole [1 ]
El-Ashry, Awad [2 ]
机构
[1] Univ Buffalo, Sch Pharm & Pharmaceut Sci, Buffalo, NY 14216 USA
[2] Buffalo Gen Med Ctr, Buffalo, NY USA
[3] Jacobs Sch Med & Biomed Sci, Buffalo, NY USA
[4] Univ Buffalo, Sch Pharm & Pharmaceut Sci, Dept Pharm Practice, Div Outcomes & Practice Advancement OPA, 202 Pharm Bldg, Buffalo, NY 14216 USA
来源
JOURNAL OF CARDIOVASCULAR SURGERY | 2023年 / 64卷 / 04期
关键词
Coronary artery bypass; Blood platelets; Hemorrhage; BYPASS SURGERY; CLOPIDOGREL; COMPLICATIONS; INHIBITION; THERAPY; UPDATE; ASSAY; RISK;
D O I
10.23736/S0021-9509.23.12595-X
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: Evidence surrounding P2Y12 platelet reactivity units (PRU) impact on bleeding outcomes in patients undergoing coronary artery bypass is varied. This study sought to assess whether on-pump CABG procedures result in increased bleeding in patients with high comMETHODS: This retrospective cohort study compared those with a PRU level 5237 (low PRU group) to >237 (high PRU group). The primary outcome assessed massive or severe bleeding in accordance with universal definition of perioperative bleeding criteria. Secondary outcomes assessed mortality, length of stay and relevant bleeding related outcomes (e.g., rates of moderate or lower classifications of bleeding, chest tube RESULTS: A total of 69 patients were included, 47 in the low and 22 in the high PRU groups. Patients were a median (IQR) 66 (62-74) years and 84.1% (N.=58) were male. Most patients received clopidogrel prior to procedure (39 [83%] in low and 18 [81.8%] in high PRU group; P=1.0000). The rate of the primary outcome was 14.9% (N.=7) in patients with a low PRU and 18.2% (N.=4) in patients with a high PRU; P=0.7345. The rate of moderate bleeding was 59.6% (N.=28) in the low and 27.3% (N.=6) in the high PRU group (P=0.0124). Packed red blood cells (PRBCs) were administered to more patients in the low (23 [48.9%]) than the high PRU group (2 [22.7%]; P=0.0388). There were no differences in other blood product requirement, chest tube output, factor products administered, mortality, or length of stay. CONCLUSIONS: This study determined that low preoperative P2Y12 PRU levels may influence moderate bleeding in patients undergoing cardiac surgery, but not massive or severe bleeding. (Cite this article as: Chilbert MR, Salah S, Kersten B, Nitsche L, Castoro N, El-Ashry A. Effect of P2Y12 platelet reactivity level on peri- and post
引用
收藏
页码:443 / 449
页数:7
相关论文
共 50 条
  • [41] VESSELWALL, BUT NOT PLATELET, P2Y12 CONTRIBUTES TO EARLY ATHEROGENESIS
    West, L.
    Francis, S.
    Storey, R.
    HEART, 2013, 99 : A7 - A7
  • [42] On-treatment platelet reactivity through the thromboxane A2 or P2Y12 platelet receptor pathways is not affected by pelacarsen
    Ewa Karwatowska-Prokopczuk
    Lu Li
    Jun Yang
    Joseph L. Witztum
    Sotirios Tsimikas
    Journal of Thrombosis and Thrombolysis, 2023, 56 : 226 - 232
  • [43] On-treatment platelet reactivity through the thromboxane A2 or P2Y12 platelet receptor pathways is not affected by pelacarsen
    Karwatowska-Prokopczuk, Ewa
    Li, Lu
    Yang, Jun
    Witztum, Joseph L.
    Tsimikas, Sotirios
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2023, 56 (02) : 226 - 232
  • [44] Central role of the P2Y12 receptor in platelet activation
    Dorsam, RT
    Kunapuli, SP
    JOURNAL OF CLINICAL INVESTIGATION, 2004, 113 (03): : 340 - 345
  • [45] Molecular mechanisms of platelet P2Y12 receptor regulation
    Cunningham, Margaret R.
    Nisar, Shaista P.
    Mundell, Stuart J.
    BIOCHEMICAL SOCIETY TRANSACTIONS, 2013, 41 : 225 - 230
  • [46] Platelet P2Y12 Is Involved in Murine Pulmonary Metastasis
    Wang, Yanhua
    Sun, Yueping
    Li, Ding
    Zhang, Lin
    Wang, Kemin
    Zuo, Yong
    Gartner, T. Kent
    Liu, Junling
    PLOS ONE, 2013, 8 (11):
  • [47] Progress in Platelet Blockers: The Target is the P2Y12 Receptor
    Patel, Prakash A.
    Lane, Bernard
    Augoustides, John G. T.
    JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA, 2013, 27 (03) : 620 - 624
  • [48] DIFFERENTIAL PLATELET ACTIVATION AFTER P2Y12 INHIBITION
    Leunissen, T. C.
    Wisman, P. P.
    van Holten, T.
    de Groot, P.
    Remijn, J.
    Frans, M.
    de Borst, G-J
    Teraa, M.
    Verhaar, M.
    Urbanus, R.
    Roest, M.
    THROMBOSIS RESEARCH, 2016, 141 : S15 - S15
  • [49] CORRELATION BETWEEN THE VERIFYNOW P2Y12 ASSAY AND LIGHT TRANSMITTANCE AGGREGOMETRY TO MEASURE PLATELET P2Y12 RECEPTOR INHIBITION IN PATIENTS ON CLOPIDOGREL THERAPY
    Ueno, Masafumi
    Ferreiro, Jose Luis
    Dharmashankar, Kodlipet
    Capranzano, Piera
    Capodanno, Davide
    Darlington, Andrew
    Bhaloo, Desai
    Charlton, Ronald
    Box, Lyndon
    Zenni, Martin
    Guzman, Luis
    Bass, Theodore
    Angiolillo, Dominick J.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2010, 55 (10)
  • [50] Usefulness of thrombelastography platelet mapping assay to measure the antiplatelet effect of P2Y12 receptor inhibitors and high on-treatment platelet reactivity
    Jeong, Young-Hoon
    Bliden, Kevin P.
    Antonino, Mark J.
    Tantry, Udaya S.
    Gurbel, Paul A.
    PLATELETS, 2013, 24 (02) : 166 - 169